rss
J Med Genet 45:314-318 doi:10.1136/jmg.2007.055475
  • Letters to JMG

Deletion of C2orf34, PREPL and SLC3A1 causes atypical hypotonia–cystinuria syndrome

  1. B Chabrol1,
  2. K Martens2,3,
  3. S Meulemans2,
  4. A Cano1,
  5. J Jaeken4,
  6. G Matthijs3,
  7. J W M Creemers2
  1. 1
    Reference Center for inborn metabolic disorders, CHU de la Timone, Marseille, France
  2. 2
    Laboratory for Biochemical Neuroendocrinology, Center for Human Genetics, University of Leuven, Belgium
  3. 3
    Laboratory for Molecular Diagnosis, Center for Human Genetics, University of Leuven, Belgium
  4. 4
    Center for Metabolic Disease, University of Leuven, Belgium
  1. Dr J Creemers, Center for Human Genetics, University of Leuven, Gasthuisberg O/N 6, box 602, Herestraat 49, B-3000 Leuven; john.creemers{at}med.kuleuven.be
  • Received 24 October 2007
  • Revised 6 December 2007
  • Accepted 7 December 2007
  • Published Online First 30 January 2008

Abstract

Background: Hypotonia–cystinuria syndrome (HCS) and 2p21 deletion syndrome are two recessive contiguous gene deletion syndromes associated with cystinuria type I. The deletions differ in size and the number of genes involved. In HCS patients, only SLC3A1 and PREPL are disrupted. In the 2p21 deletion syndrome, two additional genes (C2orf34 and PPM1B) are lost.

Objective: Clinical and molecular analysis of two siblings who presented with an atypical HCS phenotype.

Methods: Molecular analysis of the SLC3A1/PREPL locus was performed in the patients using quantitative polymerase chain reaction (PCR) methods.

Results: HCS in both siblings was confirmed with the deletion screen of the SLC3A1/PREPL locus. Fine mapping of the breakpoint revealed a deletion of 77.4 kb, including three genes: SLC3A1, PREPL and C2orf34. Features not present in classical HCS were a mild/moderate mental retardation and a respiratory chain complex IV deficiency documented in patient 2.

Conclusions: We report the first patients with a deletion of SLC3A1, PREPL and C2orf34. They present with a phenotype intermediate between HCS and 2p21 deletion syndrome. These patients facilitate the elucidation of the contribution of each gene to the phenotype in the different 2p21 deletion syndromes.

Footnotes

  • Competing interests: None declared.

  • Patient consent: Informed consent was obtained for publication of the patients’ details in this report.